Doxefazepam
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Hepatic |
Elimination half-life | 3-4 hours[1] |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C17H14ClFN2O3 |
Molar mass | 348.8 |
3D model (JSmol) | |
| |
| |
(what is this?) |
WikiDoc Resources for Doxefazepam |
Articles |
---|
Most recent articles on Doxefazepam Most cited articles on Doxefazepam |
Media |
Powerpoint slides on Doxefazepam |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Doxefazepam at Clinical Trials.gov Clinical Trials on Doxefazepam at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Doxefazepam
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Doxefazepam Discussion groups on Doxefazepam Patient Handouts on Doxefazepam Directions to Hospitals Treating Doxefazepam Risk calculators and risk factors for Doxefazepam
|
Healthcare Provider Resources |
Causes & Risk Factors for Doxefazepam |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Doxefazepam (marketed under brand name Doxans) is a benzodiazepine derivative drug developed by Schiapparelli in the 1970s.[2] It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is used therapeutically as a hypnotic.[3] According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.[4] Section 5.5 of the article Doxefazepam in volume 66 of the World Health Organization's (WHO) and International Agency for Research on Cancer's (IARC) IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the carcinogenicity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."[5]
See also
References
- ↑ http://www.intox.org/databank/documents/pharm/doxefzpm/iarc796.htm
- ↑ DE Patent 2338058 - BENZODIAZEPINVERBINDUNGEN FUER DIE THERAPIE
- ↑ Rodriguez, G; Rosadini, G; Sannita, WG; Strumia, E (1984). "Effects of doxefazepam on normal sleep. An EEG and neuropsychological study". Neuropsychobiology. 11 (2): 133–9. doi:10.1159/000118066. PMID 6483162.
- ↑ Babbini, M. (August 1975). "Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings". Arzneimittel-Forschung. 25 (8): 1294–1300. PMID 241364. Unknown parameter
|coauthors=
ignored (help) - ↑ "Doxefazepam" (PDF). IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans. International Agency For Research On Cancer (IARC). 66: 97–104. 13–20 Feb 1996. Retrieved 10 July 2014.
External links
- Pages with script errors
- Pages with citations using unsupported parameters
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- Articles with changed DrugBank identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Articles containing unverified chemical infoboxes
- Benzodiazepines
- Hypnotics
- Organochlorides
- Organofluorides
- Lactams
- Alcohols
- Drug